Cardiol Therapeutics Inc. (TSX:CRDL)
Canada · Delayed Price · Currency is CAD 1.810
-0.060 (-3.21%)
May 15, 2026, 4:00 PM EST
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2024. The number of employees increased by 12 or 200.00% compared to the previous year.
Employees
18
Change
12
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-2.02M CAD
Market Cap
202.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 18 | - | - |
| Dec 31, 2018 | 6 | - | - |
| Sep 30, 2018 | 8 | - | - |
| Jun 30, 2018 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascend Wellness Holdings | 2,300 |
| Organigram Global | 1,137 |
| Aurora Cannabis | 1,073 |
| TerrAscend | 1,038 |
| Cannara Biotech | 452 |
| Auxly Cannabis Group | 446 |
| Medexus Pharmaceuticals | 91 |
| HLS Therapeutics | 85 |
Cardiol Therapeutics News
- 5 days ago - Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - PRNewsWire
- 12 days ago - Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PRNewsWire
- 20 days ago - Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites - GuruFocus
- 20 days ago - Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network - TheFly
- 21 days ago - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - PRNewsWire
- 4 weeks ago - Cardiol Therapeutics Transcript: Study result - Transcripts
- 5 weeks ago - Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus